Future Obesity Drugs Must Provide Improved Efficacy and Safety, says GBI Research

Dec 16, 2015, 08:00 ET from GBI Research

LONDON, December 16, 2015 /PRNewswire/ --

A highly innovative and diverse pipeline of 248 products in active development is set to tackle the ever-encroaching obesity crisis, says GBI Research.

Analysis from business intelligence provider GBI Research - Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation - states that despite the current market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, with 39% of the pipeline products with disclosed molecular targets classified as first-in-class.

While most pipeline products target gut hormone receptors, the remainder target a wide range of processes thought to be dysregulated in obesity, such as angiogenesis, insulin signalling, inflammation, fat absorption, lipid synthesis, and metabolism. For a complimentary sample of this research, please visit the GBI Research website.

Senior Analyst Angel Wong: "The high level of innovation and diversity in molecular target in development is encouraging, with a number of these not only showing close alignment to the disease pathophysiology but also addressing multiple mechanisms underpinning the development of obesity.

"As obesity is a multifactorial disease, targeting multiple systems may potentially avoid compensatory mechanisms that lead to weight regain and achieve sustainable weight loss over the long term."

The analyst also says that small molecules, accounting for 66% of the overall pipeline, are the dominant molecule type in all stages of development for obesity treatment. Biologic therapeutics, consisting largely of peptides, proteins, antibodies and vaccines, also feature prominently.

GBI Research's report also states that the long-term treatment options for obesity remain sparse, including the dietary fat absorption inhibitor Xenical (orlistat), and appetite suppressants including Qsymia (phentermine and topiramate extended release), Belviq (lorcaserin hydrochloride), and the two new market entrants Contrave (naltrexone and bupropion) and Saxenda (liraglutide rDNA origin).

Wong continues: "Prescription of these treatments is generally limited, primarily due to concerns over their long-term safety, with the past decade seeing a number of drug withdrawals in the market as a result of serious cardiovascular risks and psychiatric adverse reactions.

"The uptake of anti-obesity drugs has also been hindered by their modest efficacy in inducing sustained body weight reduction. All of these factors are driving efforts to address the significant unmet need for effective obesity therapeutics with favorable safety profiles," the analyst concludes.

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

For more information, please contact GBI Research on: +44-161-359-5817

For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.

Follow GBI Research online for the latest healthcare industry updates:

Facebook | LinkedIn | Twitter